Search Results
Princess Máxima Center for Pediatric Oncology, AB Utrecht, The Netherlands
Search for other papers by Ichelle Maa van Roessel in
Google Scholar
PubMed
Princess Máxima Center for Pediatric Oncology, AB Utrecht, The Netherlands
Search for other papers by Boudewijn Bakker in
Google Scholar
PubMed
Princess Máxima Center for Pediatric Oncology, AB Utrecht, The Netherlands
Search for other papers by Hanneke M van Santen in
Google Scholar
PubMed
Search for other papers by Wassim Chemaitilly in
Google Scholar
PubMed
Childhood cancer survivors are at risk for developing endocrine disorders, including deficits in growth hormone, thyroid hormone and sex hormones. The influence these hormones have on cell growth and metabolism has raised concerns regarding the safety of their use as treatments in survivors of childhood cancer and brain tumors. This article offers a summary of current knowledge, controversies and areas for future research pertaining to this area.
Search for other papers by Alexander Heinzel in
Google Scholar
PubMed
Search for other papers by Dirk Müller in
Google Scholar
PubMed
Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands
Search for other papers by Hanneke M van Santen in
Google Scholar
PubMed
Emma Children’s Hospital, Amsterdam UMC, Department of Pediatrics, Amsterdam, The Netherlands
Search for other papers by Sarah C Clement in
Google Scholar
PubMed
Search for other papers by Arthur B Schneider in
Google Scholar
PubMed
University Hospital Würzburg, Department of Nuclear Medicine, Würzburg, Germany
Search for other papers by Frederik A Verburg in
Google Scholar
PubMed
Background
Childhood cancer survivors (CCS) who received radiation therapy exposing the thyroid gland are at increased risk of developing differentiated thyroid cancer (DTC). Therefore, the International Guideline Harmonization Group (IGHG) on late effects of childhood cancer therefore recommends surveillance. It is unclear whether surveillance reduces mortality.
Aim
The aim of this study was to compare four strategies for DTC surveillance in CCS with the aim of reducing mortality: Strategy-1, no surveillance; Strategy-2, ultrasound alone; Strategy-3, ultrasound followed by fine-needle biopsy (FNB); Strategy-4, palpation followed by ultrasound and FNB.
Materials and methods
A decision tree was formulated with 10-year thyroid cancer-specific survival as the endpoint, based on data extracted from literature.
Results
It was calculated that 12.6% of CCS will develop DTC. Using Strategy-1, all CCS with DTC would erroneously not be operated upon, but no CCS would have unnecessary surgery. With Strategy-2, all CCS with and 55.6% of CCS without DTC would be operated. Using Strategy-3, 11.1% of CCS with DTC would be correctly operated upon, 11.2% without DTC would be operated upon and 1.5% with DTC would not be operated upon. With Strategy-4, these percentages would be 6.8, 3.9 and 5.8%, respectively. Median 10-year survival rates would be equal across strategies (0.997).
Conclusion
Different surveillance strategies for DTC in CCS all result in the same high DTC survival. Therefore, the indication for surveillance may lie in a reduction of surgery-related morbidity rather than DTC-related mortality. In accordance with the IGHG guidelines, the precise strategy should be decided upon in a process of shared decision-making.
Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands
Search for other papers by Anne-Sophie C A M Koning in
Google Scholar
PubMed
Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands
Search for other papers by Philippe C Habets in
Google Scholar
PubMed
Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands
Search for other papers by Marit Bogaards in
Google Scholar
PubMed
Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands
Search for other papers by Jan Kroon in
Google Scholar
PubMed
Department of Pediatric Neuro-Oncology, Prinses Máxima Centrum, Utrecht, The Netherlands
Search for other papers by Hanneke M van Santen in
Google Scholar
PubMed
Search for other papers by Judith M de Bont in
Google Scholar
PubMed
Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands
Search for other papers by Onno C Meijer in
Google Scholar
PubMed
Background
Synthetic glucocorticoids like dexamethasone can cause severe neuropsychiatric effects. They preferentially bind to the glucocorticoid receptor (GR) over the mineralocorticoid receptor (MR). High dosages result in strong GR activation but likely also result in lower MR activation based on GR-mediated negative feedback on cortisol levels. Therefore, reduced MR activity may contribute to dexamethasone-induced neuropsychiatric symptoms.
Objective
In this single case study, we evaluate whether dexamethasone leads to reduced MR activation in the human brain. Brain tissue of an 8-year-old brain tumor patient was used, who suffered chronically from dexamethasone-induced neuropsychiatric symptoms and deceased only hours after a high dose of dexamethasone.
Main outcome measures
The efficacy of dexamethasone to induce MR activity was determined in HEK293T cells using a reporter construct. Subcellular localization of GR and MR was assessed in paraffin-embedded hippocampal tissue from the patient and two controls. In hippocampal tissue from the patient and eight controls, mRNA of MR/GR target genes was measured.
Results
In vitro, dexamethasone stimulated MR with low efficacy and low potency. Immunofluorescence showed the presence of both GR and MR in the hippocampal cell nuclei after dexamethasone exposure. The putative MR target gene JDP2 was consistently expressed at relatively low levels in the dexamethasone-treated brain samples. Gene expression showed substantial variation in MR/GR target gene expression in two different hippocampus tissue blocks from the same patient.
Conclusions
Dexamethasone may induce MR nuclear translocation in the human brain. Conclusions on in vivo effects on gene expression in the brain await the availability of more tissue of dexamethasone-treated patients.
Search for other papers by Laura van Iersel in
Google Scholar
PubMed
Search for other papers by Sarah C Clement in
Google Scholar
PubMed
Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands
Search for other papers by Antoinette Y N Schouten-van Meeteren in
Google Scholar
PubMed
Search for other papers by Annemieke M Boot in
Google Scholar
PubMed
Search for other papers by Hedi L Claahsen-van der Grinten in
Google Scholar
PubMed
Search for other papers by Bernd Granzen in
Google Scholar
PubMed
Search for other papers by K Sen Han in
Google Scholar
PubMed
Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, The Netherlands
Search for other papers by Geert O Janssens in
Google Scholar
PubMed
Search for other papers by Erna M Michiels in
Google Scholar
PubMed
Search for other papers by A S Paul van Trotsenburg in
Google Scholar
PubMed
Search for other papers by W Peter Vandertop in
Google Scholar
PubMed
Department of Pediatric Oncology/Hematology, Amsterdam University Medical Center, location VU University Medical Center, Amsterdam, The Netherlands
Search for other papers by Dannis G van Vuurden in
Google Scholar
PubMed
Search for other papers by Hubert N Caron in
Google Scholar
PubMed
Department of Pediatrics, Emma Children’s Hospital, Amsterdam University Medical Center, location Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
Search for other papers by Leontien C M Kremer in
Google Scholar
PubMed
Search for other papers by Hanneke M van Santen in
Google Scholar
PubMed
Objective
The incidence of cranial radiotherapy (cRT)–induced central hypothyroidism (TSHD) in childhood brain tumor survivors (CBTS) is reported to be low. However, TSHD may be more frequent than currently suspected, as its diagnosis is challenging due to broad reference ranges for free thyroxine (FT4) concentrations. TSHD is more likely to be present when FT4 levels progressively decline over time. Therefore, we determined the incidence and latency time of TSHD and changes of FT4 levels over time in irradiated CBTS.
Design
Nationwide, 10-year retrospective study of irradiated CBTS.
Methods
TSHD was defined as ‘diagnosed’ when FT4 concentrations were below the reference range with low, normal or mildly elevated thyrotropin levels, and as ‘presumed’ when FT4 declined ≥ 20% within the reference range. Longitudinal FT4 concentrations over time were determined in growth hormone deficient (GHD) CBTS with and without diagnosed TSHD from cRT to last follow-up (paired t-test).
Results
Of 207 included CBTS, the 5-year cumulative incidence of diagnosed TSHD was 20.3%, which occurred in 50% (25/50) of CBTS with GHD by 3.4 years (range, 0.9–9.7) after cRT. Presumed TSHD was present in 20 additional CBTS. The median FT4 decline in GH-deficient CBTS was 41.3% (P < 0.01) to diagnosis of TSHD and 12.4% (P = 0.02) in GH-deficient CBTS without diagnosed TSHD.
Conclusions
FT4 concentrations in CBTS significantly decline over time after cRT, also in those not diagnosed with TSHD, suggesting that TSHD occurs more frequently and earlier than currently reported. The clinical relevance of cRT-induced FT4 decline over time should be investigated in future studies.